BHC(SH:600721) Sou Hu Cai Jing·2025-11-05 18:34Summary of Key Points Core Viewpoint - Baohua Pharmaceutical (600721) is taking measures to improve its financial situation by utilizing its surplus reserves to offset accumulated losses, which is aimed at enhancing its ability to distribute profits and increase investor returns [1][3]. Trading Information - On November 5, Baohua Pharmaceutical closed at 8.97 yuan, with a slight increase of 0.22%. The turnover rate was 2.24%, with a trading volume of 86,200 shares and a total transaction amount of 76.93 million yuan [1]. - On the same day, the net outflow of main funds was 4.57 million yuan, accounting for 5.94% of the total transaction amount. Retail investors saw a net inflow of 5.99 million yuan, representing 7.79% of the total transaction amount [1][3]. Company Announcement - Baohua Pharmaceutical plans to use its surplus reserves to cover losses. As of December 31, 2024, the company's accumulated undistributed profits amounted to -1,910,537,976.55 yuan. The company intends to use 5,030,274.41 yuan from surplus reserves and 1,905,507,702.14 yuan from capital reserves, totaling 1,910,537,976.55 yuan, to offset these losses [1]. - Following this plan, the surplus reserves will be reduced to 0 yuan, and the capital reserves will decrease to 354,773,156.72 yuan, with undistributed profits also reaching 0 yuan. This proposal has been submitted for review at the second extraordinary shareholders' meeting in 2025 [1].